FPC
KERX

Falcon Point Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Falcon Point Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-251,137
Closed -$2.51M – 134
2015
Q2 		$2.51M Buy
251,137
+181,448
+260% +$1.95M 0.85% 44
2015
Q1 		$887K Buy
+69,689
New +$896K 0.69% 59

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Falcon Point Capital's KERX Position: Q3 2015 in Review

Falcon Point Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 251,137 shares — an estimated $2.51M sold.

Falcon Point Capital first reported a position in KERX in Q1 2015 and held it in 2 quarters. The position peaked at $2.51M in Q2 2015. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • Falcon Point Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Falcon Point Capital sold 251,137 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $2.51M.
  • Falcon Point Capital first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 2 quarters.
  • Falcon Point Capital's Keryx Biopharmaceuticals Inc position peaked at $2.51M in Q2 2015.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Falcon Point Capital's 13F filing for Q3 2015, filed 20 Oct 2015.